AAV-derived HSV-specific transferred mAbs protect pups from nHSV mortality . AAVs encoding four different mAb sequences were administered to female mice. Progeny were assessed for Ab transfer and protection from viral challenge. (A) Schematic of AAV human IgG expression vector structure and experimental approach. (B) Detection of in vivo expressed huIgG in the serum of AAV-administered female mice from two different litters, week 0 through 4, CH42 (n = 2), CH43 (n = 2), E317 (n = 3), and IgG ctrl (n = 3). (C) Biodistribution of human IgG in the viscera, brain, trigeminal ganglia, and serum of offspring of AAV-treated dams, each symbol represents a pup, CH42 (dam n = 2, two litters, pup n = 4), CH43 (dam n = 1, one litter, pup n = 3), E317 (dam n = 3, three litters, pup n = 6), IgG ctrl (dam n = 3, three litters, pup n = 8), the bars represent geometric mean. Signal is reported as the fold increase in human IgG in treated pups relative to untreated controls. (D) Survival of progeny of AAV-administered dams challenged with 1 × 10⁴ PFU of HSV-1 2 d post-partum, CH42 (dam n = 2, two litters, pup n = 14), CH43 (dam n = 2, two litters, pup n = 14), E317 (dam n = 3, three litters, pup n = 18), IgG ctrl (dam n = 3, three litters, pup n = 19). Statistical significance was determined by the Log-rank (Mantel-Cox) test; HSV-specific mAbs are compared to IgG control (ctrl; ***, P < 0.001). Serum (SRM), stomach (STM), lung (LNG), liver (LVR), heart (HRT), kidney (KD), spleen (SPL), trigeminal ganglia (TG), brain (BRN).